Literature DB >> 8119350

Patient and strain characteristics in relation to the outcome of meningococcal disease: a multivariate analysis.

R J Scholten1, H A Bijlmer, H A Valkenburg, J Dankert.   

Abstract

To investigate the joint association of patient and strain characteristics with the outcome of meningococcal disease (MD), data were collected on 563 consecutive cases of MD reported between 1989 and 1990 in The Netherlands. The meningococcal isolates were characterized with regard to their surface characteristics. Sequelae occurred in 8.5% of the patients, and were only associated with the presence of bacteraemia. The case-fatality rate was 7.7%. Infants aged < or = 5 months and patients in the age-groups of 10-19 years and > or = 50 years had an increased risk for a fatal outcome compared with children from 6 months to 9 years old (Odds Ratios [ORs]: 5.1, 3.4 and 9.8, respectively). The OR for females versus males was 2.3. The ORs for patients with bacteraemia, or a combination of bacteraemia and meningitis, compared with meningitic patients, were 2.3 and 3.1. Meningococcal strain characteristics did not influence the case-fatality rate substantially. In conclusion, host factors were found to be determinants for a fatal outcome of MD in The Netherlands from 1989 to 1990.

Entities:  

Mesh:

Year:  1994        PMID: 8119350      PMCID: PMC2271487          DOI: 10.1017/s0950268800057472

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  19 in total

1.  Serological typing of meningococci by means of micro-precipitation.

Authors:  K W SLATERUS
Journal:  Antonie Van Leeuwenhoek       Date:  1961       Impact factor: 2.271

Review 2.  Polysaccharides and membrane vaccines.

Authors:  J T Poolman
Journal:  Adv Biotechnol Processes       Date:  1990

Review 3.  Endotoxin release from neisseria meningitidis. Relationship between key bacterial characteristics and meningococcal disease.

Authors:  B M Andersen
Journal:  Scand J Infect Dis Suppl       Date:  1989

4.  Meningococcal infections in Scotland 1972-82.

Authors:  R J Fallon; W M Brown; W Lore
Journal:  J Hyg (Lond)       Date:  1984-10

5.  Meningococcal disease in Wales: clinical features, outcome and public health management.

Authors:  S R Palmer; J Corson; R Hall; S Payne; J Ludlow; B Deere; H Jones; S Kaul; J Stubbins; R Williams
Journal:  J Infect       Date:  1992-11       Impact factor: 6.072

6.  Mortality in meningococcal disease in Belgium.

Authors:  P De Wals; L Hertoghe; G Reginster; I Borlee; A Bouckaert; A Dachy; M F Lechat
Journal:  J Infect       Date:  1984-05       Impact factor: 6.072

7.  Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis.

Authors:  R J Scholten; H A Bijlmer; J T Poolman; B Kuipers; D A Caugant; L Van Alphen; J Dankert; H A Valkenburg
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

Review 8.  Meningococcal disease: still with us.

Authors:  H Peltola
Journal:  Rev Infect Dis       Date:  1983 Jan-Feb

9.  Meningococcal infections: reducing the case fatality rate by giving penicillin before admission to hospital.

Authors:  J R Strang; E J Pugh
Journal:  BMJ       Date:  1992-07-18

10.  Early treatment with parenteral penicillin in meningococcal disease.

Authors:  K Cartwright; S Reilly; D White; J Stuart
Journal:  BMJ       Date:  1992-07-18
View more
  11 in total

Review 1.  The immunopathogenesis of meningococcal disease.

Authors:  A J Kvalsvig; D J Unsworth
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.

Authors:  Gary M Ginsberg; Colin Block; Chen Stein-Zamir
Journal:  Int J Public Health       Date:  2016-04-22       Impact factor: 3.380

Review 3.  Bacterial meningitis in children: critical review of current concepts.

Authors:  Ram Yogev; Judith Guzman-Cottrill
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002.

Authors:  I Smith; A T Bjørnevik; I M B Augland; A Berstad; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

5.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

6.  Dynamics of childhood invasive meningococcal disease in Israel during a 22-year period (1989-2010).

Authors:  S Ben-Shimol; R Dagan; Y Schonmann; N Givon-Lavi; N Keller; C Block; I Kassis; M Ephros; D Greenberg
Journal:  Infection       Date:  2013-03-10       Impact factor: 3.553

7.  Epidemiology of meningococcal disease in Switzerland, 1999-2002.

Authors:  H Jaccard Ruedin; B Ninet; E Pagano; P Rohner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-22       Impact factor: 3.267

8.  Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

Authors:  D M Granoff; S K Kelsey; H A Bijlmer; L Van Alphen; J Dankert; R E Mandrell; F H Azmi; R J Scholten
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.

Authors:  Koen B Pouwels; Eelko Hak; Arie van der Ende; Hannah Christensen; Germie P J M van den Dobbelsteen; Maarten J Postma
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

10.  Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.

Authors:  Hiltsje Hepkema; Koen B Pouwels; Arie van der Ende; Tjalke A Westra; Maarten J Postma
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.